Todos os estudos
AutorizadoFase I e Fase II (Integrado) - OutrosIntervencionista

Phase I/II combination umbrella trial in progressive/relapsed/refractory pediatric low-grade glioma (pLGG) (EPILOGUE)

This research study, called EPILOGUE, is exploring new ways to treat children and young people who have a specific type of brain tumour called paediatric low-grade glioma (pLGG). This is for cases where the tumour has either returned, grown, or hasn't responded to previous treatments. Researchers are testing different combinations of medicines, specifically Vinblastine Sulfate Teva and Tovorafenib, to see how safe they are together and how well they work at shrinking the tumour. The study will involve regular check-ups over about two years, looking at how patients respond and any side effects they might experience. The goal is to find better treatment options for these young patients.

Em resumo

Status
Autorizado
Fase
Fase I e Fase II (Integrado) - Outros
Patrocinador
Universitaetsklinikum Heidelberg AöR
Meta de inscrição
34
Iniciar
17 Mar 2026

Sobre o que é este estudo?

This study is called EPILOGUE, and it's looking into new ways to help children and teenagers with a type of brain tumour called paediatric low-grade glioma (pLGG). This kind of tumour sometimes grows or comes back even after treatment, or doesn't react to treatment in the first place. When this happens, doctors need more options, and that's exactly what this study is trying to find.

Researchers are testing combinations of two specific medicines: Vinblastine Sulfate Teva and Tovorafenib. Both these drugs are already used to treat certain conditions, but the study wants to see if using them together is a safe and effective way to fight pLGG. They will be carefully watching for any side effects and seeing if the tumours shrink or stop growing.

The main aim is to understand the safest doses of these combined treatments and how well they make the tumour respond. They will be checking patients regularly to see how things are going and to make sure the treatment is as safe and helpful as possible. Information from studies like EPILOGUE helps doctors learn how to give the best care to young people with brain tumours.

Pontos principais

  • Tests new combination treatments for a type of brain tumour (pLGG).
  • Aimed at helping tumours that have come back or are getting worse.
  • Uses existing medicines: Vinblastine Sulfate Teva and Tovorafenib.
  • Monitors safety and how well tumours respond to treatment.
  • Participation involves regular check-ups for up to two years.

Quem pode ser elegível?

This study is open to both male and female patients who are 18 years old or older. You could be considered for this study if you have paediatric low-grade glioma (pLGG) that has either progressed (gotten worse), relapsed (come back), or is refractory (hasn't responded well to previous treatments).

The term "paediatric" in pLGG refers to the type of tumour which usually starts in childhood, but the study itself is for adults who still have this condition. Your doctors will need to check other specific medical requirements to make sure this study is the right fit for you.

Este estudo pode ser adequado para você?

Responda a estas perguntas rápidas para ver se você pode ser elegível. Este é apenas um guia — a decisão final é da equipe de pesquisa.

  1. Tenho 18 anos ou mais?
  2. Do I have paediatric low-grade glioma (pLGG)?
  3. Has my pLGG come back, gotten worse, or not responded to previous treatments?
  4. Am I able to attend regular appointments for scans and check-ups?
Responda a todas as perguntas para ver o seu resultado.

O que envolve a participação?

If you decide to take part in this study, you will receive either Vinblastine Sulfate Teva, Tovorafenib, or a combination of both. You will have regular appointments, likely every 8 weeks, for about two years. During these visits, doctors will monitor your health, check for any changes in your tumour using scans, and look for any side effects from the medication. You will be on the study treatment for up to 12 cycles, which is about 24 months. After this, you will still have follow-up checks to see how you're doing in the long term. All medication and tests related to the study will be provided.

Riscos e benefícios potenciais

Taking part in a study like this might offer a chance to try new treatments that aren't widely available yet, which could potentially help shrink your tumour or control its growth. However, all medicines have potential side effects, and combining them might bring new or stronger side effects. The research team will carefully monitor you for any problems. You're always in control; you have the right to leave the study at any time, for any reason, without it affecting your medical care.

Localizações (5)

Algumas localizações dos sites são aproximadas. Estamos melhorando isso — por favor, verifique com a equipe de teste antes de viajar.
  • —
    Não verificado
    Dinamarca
  • —
    Não verificado
    Chéquia
  • —
    Não verificado
    Áustria
  • —
    Não verificado
    Suécia
  • —
    Não verificado
    Alemanha

Perguntas frequentes

What is paediatric low-grade glioma (pLGG)?

It's a type of slow-growing brain tumour that typically starts in children, but can continue to affect people into adulthood.

Are the study drugs new?

Vinblastine Sulfate Teva and Tovorafenib are existing medicines, but this study is looking at using them together in new combinations for pLGG.

Quanto tempo estarei no estudo?

You could be on the study treatment for up to 12 cycles (about 2 years), with follow-up appointments after that.

What kind of tests will I have?

You'll have regular scans and check-ups to see how the tumour is responding and to monitor your overall health and any side effects.

Posso parar de participar se eu quiser?

Sim, você pode optar por sair do estudo a qualquer momento, e isso não afetará seu tratamento médico em andamento.

Como saber mais

Sempre consulte seu médico ou especialista antes de decidir participar de um estudo.

Discussão

Discussão da comunidade

Desenvolvido pelo nosso fórum em community.patient.info. Por favor, seja respeitoso — isto não é um conselho médico.